| Drug Name |
Zafirlukast |
| Drug ID |
BADD_D02377 |
| Description |
Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily.
Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. |
| Indications and Usage |
For the prophylaxis and chronic treatment of asthma. |
| Marketing Status |
approved; investigational |
| ATC Code |
R03DC01 |
| DrugBank ID |
DB00549
|
| KEGG ID |
D00411
|
| MeSH ID |
C062735
|
| PubChem ID |
5717
|
| TTD Drug ID |
D05DVP
|
| NDC Product Code |
16571-654; 49884-589; 64380-187; 68084-059; 55111-625; 65977-0113; 64380-178; 31722-008; 49884-554; 49884-590; 63629-2102; 64380-188; 42291-970; 52562-800; 55111-886; 55111-626; 52562-801; 31722-007; 64380-177; 50370-0008; 42291-971; 49884-549 |
| UNII |
XZ629S5L50
|
| Synonyms |
zafirlukast | 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N-O-tolylsulfonylbenzamide | Olmoran | ICI 204,219 | ICI-204219 | ICI 204219 | Accolate | Aeronix |
